Lexicon Pharmaceuticals (LXRX) Citigroup’s Biopharma Back to School Summit 2026 summary

Strategic focus and leadership updates

• Emphasis on R&D, financial flexibility, and partnerships, with a focus on sotagliflozin (SOTA) and commercial readiness for HCM opportunities.

• Rachel Martens promoted to Chief Commercial Officer, forming a lean commercial team to prepare for HCM launch.

• Head of marketing and market access roles established to support pre-launch activities.

SONATA-HCM phase III trial and expectations

• SONATA-HCM trial data expected in Q1 2027, with over-enrollment improving statistical power.

• Primary endpoint is KCCQ score improvement; a three-point delta vs. placebo is considered a commercial success.

• Trial includes both obstructive and non-obstructive HCM patients, analyzed as a single group, with more non-obstructive patients enrolled.

• Secondary endpoints include NYHA score, echo parameters, and cardiac enzymes, with confidence in benefit across these measures.

• Data will also provide insights on patients using both SOTA and cardiac myosin inhibitors (CMIs).

Commercial and regulatory insights

• Significant commercial opportunity identified in non-obstructive HCM due to lack of alternatives and low bar for success.

• Continued enthusiasm in obstructive HCM, with potential for SOTA as add-on or first-line therapy.

• More granular guidance on data timing expected at the start of next year.